How it works
Selectively activates MC4R in the hypothalamus, increasing dopaminergic signalling in the medial preoptic area — driving desire itself rather than blood flow, unlike PDE5 inhibitors.
Structure: Cyclic heptapeptide, Melanotan II metabolite
Reported benefits
- Increased sexual desire in both sexes
- Works independently of vascular function
- Effective as an on-demand dose
Practical considerations
- Raises blood pressure transiently — avoid with uncontrolled hypertension
- Nausea is common at higher doses
- Label limits use to eight doses per month
Side effects and risks
- Nausea and vomiting
- Flushing
- Headache
- Transient blood-pressure increase
PT-141 dosing overview
1.75 mg as needed, maximum one dose per 24 hours
| Context | Amount | Frequency | Route |
|---|---|---|---|
| Approved label dose (Vyleesi) | 1.75 mg | As needed, max 1 dose / 24h and 8 per month | Subcutaneous auto-injector |
| Timing | — | About 45 minutes before activity | — |
This describes doses reported in published literature and community protocols. It is not a recommendation, and it is not a substitute for clinical supervision.
PT-141 FAQ
How does PT-141 differ from sildenafil?
It works centrally on melanocortin receptors in the brain to affect desire and arousal, rather than peripherally on blood flow. That makes it a different mechanism, not a stronger version of the same one.
How long does it last?
Plasma half-life is around 2.7 hours, but the reported window of effect is commonly described as several hours to a day after a dose.
What are the common side effects?
Nausea is the most frequent, followed by flushing, headache and injection-site reactions. Transient blood-pressure increases are documented, so it is avoided in uncontrolled hypertension.
Is it approved for men?
The approval (Vyleesi) covers premenopausal women with hypoactive sexual desire disorder. Use in men is off-label.
Research references
- Kingsberg et al., 2019 — RECONNECT trials of bremelanotide